Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

4 Issues per year


IMPACT FACTOR 2016: 1.148

CiteScore 2016: 0.84

SCImago Journal Rank (SJR) 2016: 0.279
Source Normalized Impact per Paper (SNIP) 2016: 0.488

Open Access
Online
ISSN
1452-8266
See all formats and pricing
More options …
Volume 30, Issue 3 (Jul 2011)

Issues

Biomarkers for Diabetes Complications: The Results of Several Clinical Studies

Diler Aslan
Published Online: 2011-06-21 | DOI: https://doi.org/10.2478/v10011-011-0024-4

Biomarkers for Diabetes Complications: The Results of Several Clinical Studies

Diabetes is a common metabolic disorder. Its microvascular and macrovascular complications contribute to death, disabilities, and reduction in life expectancy in diabetes. It is a costly disease, and affects not only the patient and family, but also the public health, communities and society. It takes an increasing proportion of the national health care expenditure. The prevention of the development of diabetes and its complications is a major concern. Biomarkers have been investigated for understanding the mechanisms of the development and progression of diabetic complications. In this paper, the biomarkers which are recommended in the clinical practice and laboratory medicine guidelines, and which have been investigated for prediction or diagnosis of diabetes complications, have been reviewed. The results of several clinical studies will be summarized.

Biomarkeri Komplikacija u Dijabetesu: Rezultati Nekoliko Kliničkih Studija

Dijabetes predstavlja čest metabolički poremećaj, čije mikrovaskularne i makrovaskularne komplikacije doprinose smrti, invaliditetu i skraćenju očekivanog životnog veka kod obolelih. Ova bolest podrazumeva velike troškove a pored pacijenta i njegove porodice pogađa i javno zdravlje, zajednice i društvo. Dijabetes zahteva sve veći deo nacionalnih troškova zdravstva. Prevencija razvoja dijabetesa i njegovih komplikacija je važan problem. U cilju razumevanja mehanizama razvoja i progresije komplikacija u dijabetesu vrši se istraživanje biomarkera. U ovom radu dat je pregled biomarkera koji se preporučuju u kliničkoj praksi i pravilnicima za laboratorijsku medicinu i koji su istraživani radi predikcije ili dijagnostikovanja komplikacija u dijabetesu. U sažetom obliku su prikazani rezultati nekoliko kliničkih studija.

Keywords: diabetes; biomarkers; clinical studies

Keywords: dijabetes; biomarkeri; kliničke studije

  • International Diabetes Association. Global Burden: Prevalence and Projections, 2010 and 2030. IDF Diabetes Atlas. http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance

  • International Diabetes Association. Morbidity and Mortality. IDF Diabetes Atlas. http://www.diabetesatlas.org/content/diabetes-mortality

  • International Diabetes Association. The Economic Impacts of Diabetes. IDF Diabetes Atlas. http://www.dia-betesatlas.org/content/economic-impacts-diabetes

  • Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28 (9): 2130-5.PubMedCrossrefGoogle Scholar

  • Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (6): 1615-25.PubMedCrossrefGoogle Scholar

  • Marshall S, Flyvbjerg A. Prevention and early detection of vas cular complications of diabetes. BMJ 2006; 333: 475-80.Google Scholar

  • King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79 (8 Suppl): 1527-34.CrossrefPubMedGoogle Scholar

  • Lin J, Hu FB, Mantzoros C, Curhan GC. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010; 53 (2): 263-7.CrossrefPubMedGoogle Scholar

  • Kolberg JA, Jörgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 2009; 32 (7): 1207-12.Google Scholar

  • Beisswenger PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2010. Doi: 10.1007/s00726-010-0784-z.PubMedCrossrefGoogle Scholar

  • Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010; 3 (2): 101-8.CrossrefPubMedGoogle Scholar

  • Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011. doi:10.1016/j.semcdb.2011.02.015.PubMedCrossrefGoogle Scholar

  • Takeuchi M, Takino J, Yamagishi S. Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol 2010; 1-12. doi:10.1155/2010/170393.CrossrefGoogle Scholar

  • Lam CS, Benzie IF, Choi SW, Chan LY, Yeung VT, Woo GC. Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci 2011 Feb; 88 (2): 251-6.CrossrefGoogle Scholar

  • Vicentini J, Valentini J, Grotto D, Paniz C, Roehrs M, Brucker N, et al. Association among microalbuminuria and oxidative stress biomarkers in patients with type 2 diabetes. J Investig Med 2011: 1-6.Google Scholar

  • Sharma RK, Rogojina AT, Chalam KV. Multiplex immunoassay analysis of biomarkers in clinically accessible quantities of human aqueous humor. Mol Vis 2009; 15: 60-9.PubMedGoogle Scholar

  • Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 2010; 10 (1): 37-42.PubMedCrossrefGoogle Scholar

  • Snell-Bergeon JK, Maahs DM, Ogden LG, Kinney GL, Hokanson JE, Schiffer E, et. al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009; 11 (1): 1-9.CrossrefGoogle Scholar

  • Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010 Mar; 26 (3): 150-71.CrossrefPubMedGoogle Scholar

  • Scott EM, Carter AM, Findlay JB. The application of proteomics to diabetes. Diab Vasc Dis Res 2005 May; 2 (2): 54-60.Google Scholar

  • Sundsten T, Eberhardson M, Göransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006; 12; 4: 22.CrossrefGoogle Scholar

  • Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30 (3): 638-43.CrossrefGoogle Scholar

  • Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM. The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2 (7-8): 997-1007.CrossrefPubMedGoogle Scholar

  • Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19 (7): 1283-90.PubMedCrossrefGoogle Scholar

  • Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20 (9): 2065-74.CrossrefPubMedGoogle Scholar

  • Ameur RB, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Trans plant 2010; 25 (9): 2866-75.Google Scholar

  • Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes re search: moving from information to knowledge. Diabetes 2009 Nov; 58 (11): 2429-43.CrossrefGoogle Scholar

  • Benito-Martín A, Ucero AC, Santamaría B, Lorz C, Kretzler M, Rastaldi MP, et al. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy. Nefrologia 2009; 29 (1): 13-19.Google Scholar

  • Meikle PJ, Tsorotes D, Barlow CK, Weir J, MacIntosh GL, Barber M, et al. Plasma lipidomic analysis for prediction of unstable coronary artery disease. [Abstract] Circulation 2010; 122: A15009.Google Scholar

  • Shi Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. Journal of Biomedical Research 2010; 24 (1): 6-15.Google Scholar

  • Sorensen CM, Ding J, Zhang Q, Alquier T, Zhao R, Mueller PW, Smith RD, Metz TO. Perturbations in the lipid profile of individuals with newly diagnosed type 1 diabetes mellitus: lipidomics analysis of a Diabetes Antibody Standardization Program sample subset. Clin Biochem 2010; 43 (12): 948-56.PubMedCrossrefGoogle Scholar

  • Priego-Capote F, Scherl A, Müller M, Waridel P, Lisacek F, Sanchez JC. Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010; 9 (3): 579-92.CrossrefGoogle Scholar

  • Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, et al. Association between PON 1 poly morphisms, PON activity and diabetes complications. J Diabetes Complications 2006 Sep-Oct; 20 (5): 322-8.CrossrefGoogle Scholar

  • Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-41.PubMedGoogle Scholar

  • Kazemi Arababadi M. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 2010 Oct; 4 (4): 302-6.Google Scholar

  • Balasubbu S, Sundaresan P, Rajendran A, Ramasamy K, Govindarajan G, Perumalsamy N, et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet 2010; 10 (11): 158.CrossrefGoogle Scholar

  • Jaziri R, Aubert R, Roussel R, Emery N, Maimaitiming S, Bellili N, et al; DIABHYCAR and SURDIAGENE Study Groups. Association of ADIPOQ genetic variants and plas ma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 2010 Jul; 25 (7): 2231-7.Google Scholar

  • Jiang YD, Chang YC, Chiu YF, Chang TJ, Li HY, Lin WH, et al. SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes. BMC Med Genet 2010; 11: 126.CrossrefGoogle Scholar

  • Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304 (8): 881-9.CrossrefGoogle Scholar

  • Yang Y, Andresen BT, Yang K, Zhang Y, Li X, Li X, et al. Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood) 2010; 235 (10): 1204-11.CrossrefGoogle Scholar

  • Stankov K. Genetic predisposition for type 1 diabetes mellitus - The role of endoplasmic reticulum stress in human disease etiopathogenesis. Journal of Biomedical Biochemistry 2010; 29: 139-149.Google Scholar

  • Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011 Feb 9; 10(1):16.Google Scholar

  • Hamet P, Tremblay J. Will ADVANCE population genomic determinants improve upon biomarkers in predicting vascular complications of diabetes? Medicographia 2009; 31: 307-13.Google Scholar

  • Golubnitschaja O. Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA Journal 2010; 1: 3-12.CrossrefGoogle Scholar

  • Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem 2011 Feb; 57 (2): 231-40.PubMedCrossrefGoogle Scholar

  • American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33 (Suppl): S11-61.Google Scholar

  • Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, M, Kirkman S, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. DRAFT November 2010 Version. NACB: Laboratory Medicine Practice Guidelines (LMPG) http://www.aacc.org/members/nacb/lmpg/pages/default.aspx (Accessed: 2010). http://www.aacc.org/members/nacb/lmpg/pages/default.aspx

  • Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Alan C, et al. National Evidence Based Guideline for Diag nosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.Google Scholar

  • Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, Akhtar MW. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 2010 Dec; 12 (12): 979-88.CrossrefPubMedGoogle Scholar

  • DPK Ng. Human Genetics of Diabetic Retinopathy: Current Perspectives. Journal of Ophthalmology 2010: 1-6.Google Scholar

  • Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia (2011) 54: 803-11.CrossrefGoogle Scholar

  • Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Invest 2010; 1 (3): 90-6.CrossrefGoogle Scholar

  • Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33 (12): 2561-6.PubMedCrossrefGoogle Scholar

  • Nakamura S, Morishita R, Moriguchi A, Yo Y, Nakamura Y, Hayashi S, et al. Hepatocyte growth factor as a potential index of complication in diabetes mellitus. Hypertens 1998; 16: 2019-26.Google Scholar

  • Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Kohri K, et al. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes. Diabet Med 2006; 23: 617-22.CrossrefPubMedGoogle Scholar

  • Van der Zijl NJ, Hanemaaijer R, Tushuizen ME, Schindhelm RK, Boerop J, Rustemeijer C, et al. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy? Clin Biochem 2010; 43 (7-8): 635-9.Google Scholar

  • Oh JY. Serum cystatin C as a biomarker for predicting coronary artery disease in diabetes. Korean Diabetes J 2010; 34 (2): 84-5.PubMedCrossrefGoogle Scholar

  • True MW. Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. J Diabetes Sci Technol 2009; 3 (4): 743-7.PubMedGoogle Scholar

  • Pal A, Farmer AJ, Dudley C, Selwood MP, Barrow BA, Klyne R, et al. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 2010; 33 (2): 252-7.PubMedCrossrefGoogle Scholar

  • Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32 (2): 91-8.Google Scholar

  • Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci 2011; 341 (1): 28-32.Google Scholar

  • Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional Markers of Glycemia: Associations with microvascular conditions. Diabetes Care [Abstract]. 2011. doi: 10.2337/dc10-1945.CrossrefGoogle Scholar

About the article


Published Online: 2011-06-21

Published in Print: 2011-07-01


Citation Information: Journal of Medical Biochemistry, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: https://doi.org/10.2478/v10011-011-0024-4.

Export Citation

This content is open access.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Daniela Gradinaru, Claudia Borsa, Cristina Ionescu, and Denisa Margina
Journal of Proteomics, 2013, Volume 92, Page 313
[2]
Dragana Robajac, Romana Masnikosa, Dejan Filimonović, Željko Miković, and Olgica Nedić
Journal of Medical Biochemistry, 2012, Volume 31, Number 3
[3]
Mirjana Bećarević, Jelena Seferović, Svetlana Ignjatović, Sandra Singh, and Nada Majkić-Singh
Journal of Medical Biochemistry, 2012, Volume 31, Number 3
[4]
N. Radovanovic, N. Antonijevic, A. Beletic, J. Perunicic, M. Kocica, D. Mirkovic, Vesna Lackovic, and Maja Lackovic
Archives of Biological Sciences, 2010, Volume 62, Number 4, Page 907
[5]
Prathima Sindhu, Beena Shetty, K Sudha, and Gayathri Rao
Journal of Medical Biochemistry, 2012, Volume 31, Number 2
[6]
Nada Majkić-Singh
Journal of Medical Biochemistry, 2011, Volume 30, Number 3
[7]
Nada Majkić-Singh
Journal of Medical Biochemistry, 2011, Volume 30, Number 3

Comments (0)

Please log in or register to comment.
Log in